Complete response of stage IV pancreatic cancer combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia. (March 2019) - Kleef, R.; Nagy, R.; Bohdjalian, A.; Bacher, V.; Wychera, A.; Kekic, S.; McKee, D.; Bojar, H.; Moss, R.